Avutometinib Evidence: Trial Results and Peer-Reviewed Publications

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

1. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
   McNamara B, Demirkiran C, Hartwich TMP, et al. · Gynecol Oncol · 2024
   PubMed: PMID 38493021 · NCT04625270 (RAMP 201) · Ovarian Neoplasms
2. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
   Grisham R, Monk BJ, Van Nieuwenhuysen E, et al. · Int J Gynecol Cancer · 2025
   PubMed: PMID 39375168 · NCT06072781 (RAMP 301)
3. Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas.
   Del Valle MM, Colon EM, Kettimuthu K, et al. · Cancer Chemother Pharmacol · 2026
   PubMed: PMID 41790275 · NCT05798507 · Glioblastoma
4. Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.
   Capelletto E, Bironzo P, Denis L, et al. · Future Oncol · 2022
   PubMed: PMID 35285277 · NCT04620330 (RAMP202) · Carcinoma, Non-Small-Cell Lung
5. The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
   Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. · Future Oncol · 2026
   PubMed: PMID 41384753 · NCT06072781 (RAMP 301)
6. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
   Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. · J Clin Oncol · 2025
   PubMed: PMID 40644648 · NCT06072781 (RAMP 301)

Publications by year

2022–2026: 6 publications.

Publications by indication

Publications by journal

• Future Oncol2 papers
• Gynecol Oncol1 paper
• Int J Gynecol Cancer1 paper
• Cancer Chemother Pharmacol1 paper
• J Clin Oncol1 paper

All Avutometinib publications (6)

Sources and methodology

• Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
• Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
• Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
• Data freshness: Wed, 27 May 2026 18:55:13 GMT.